Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma
Status:
Terminated
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to to compare the addition of sorafenib (800 mg/day)to best
supportive care with best supportive care alone in terms of survival in patients with
hepatocellular carcinoma (HCC) with impaired liver function (Child B).